KR20140145173A - 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커 - Google Patents

알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커 Download PDF

Info

Publication number
KR20140145173A
KR20140145173A KR1020147029916A KR20147029916A KR20140145173A KR 20140145173 A KR20140145173 A KR 20140145173A KR 1020147029916 A KR1020147029916 A KR 1020147029916A KR 20147029916 A KR20147029916 A KR 20147029916A KR 20140145173 A KR20140145173 A KR 20140145173A
Authority
KR
South Korea
Prior art keywords
cd11b
lin
cells
level
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147029916A
Other languages
English (en)
Korean (ko)
Inventor
미카엘 아이젠바흐-슈와르츠
이스터 욜레스
Original Assignee
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드
뉴로퀘스트 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드, 뉴로퀘스트 엘티디 filed Critical 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드
Publication of KR20140145173A publication Critical patent/KR20140145173A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020147029916A 2012-03-26 2013-03-21 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커 Withdrawn KR20140145173A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615465P 2012-03-26 2012-03-26
US61/615,465 2012-03-26
PCT/IL2013/050277 WO2013144957A1 (en) 2012-03-26 2013-03-21 Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression

Publications (1)

Publication Number Publication Date
KR20140145173A true KR20140145173A (ko) 2014-12-22

Family

ID=49258360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147029916A Withdrawn KR20140145173A (ko) 2012-03-26 2013-03-21 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커

Country Status (10)

Country Link
US (1) US20150057176A1 (enExample)
EP (1) EP2831584B1 (enExample)
JP (1) JP6276252B2 (enExample)
KR (1) KR20140145173A (enExample)
CN (1) CN104471394B (enExample)
AU (1) AU2013239070A1 (enExample)
CA (1) CA2907909A1 (enExample)
ES (1) ES2819174T3 (enExample)
IL (1) IL234779A (enExample)
WO (1) WO2013144957A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6312302B2 (ja) * 2014-01-06 2018-04-18 公益財団法人ヒューマンサイエンス振興財団 脳梗塞の診断マーカー
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
JP6499342B2 (ja) * 2018-03-19 2019-04-10 隆樹 日和佐 脳梗塞の診断マーカー
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
WO2020198299A1 (en) * 2019-03-26 2020-10-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for characterizing and treating alzheimer's disease
CN111727260A (zh) * 2019-10-15 2020-09-29 湖南乾康科技有限公司 中间型单核细胞在制备诊断和预测ad药物中的应用
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
CN112562867A (zh) * 2021-02-22 2021-03-26 天津迈德新医药科技有限公司 一种预测极早期hiv感染风险的装置、存储介质和电子装置
EP4426295A1 (en) * 2021-11-02 2024-09-11 Tranquis Therapeutics, Inc. Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype
KR102745500B1 (ko) * 2022-09-02 2024-12-23 한양대학교 에리카산학협력단 혈액 대사체를 이용한 치매 스크리닝 장치 및 방법
CN116270741B (zh) * 2023-02-28 2025-10-24 东莞市东南部中心医院 骨髓源性抑制细胞在制备治疗阿兹海默症药物或试剂中的应用
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US20020137108A1 (en) * 2000-11-08 2002-09-26 Michael Mullan CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease
KR20040081431A (ko) * 2001-12-06 2004-09-21 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 운동신경 질환의 치료용 백신 및 치료 방법
ES2350895T3 (es) * 2004-08-19 2011-01-28 University College Cardiff Consultants Limited Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia.
MX349711B (es) * 2008-09-18 2017-08-09 Cedars Sinai Medical Center Método óptico para la detección de la enfermedad de alzheimer.
CA2792471A1 (en) 2010-03-10 2011-09-15 Yeda Research And Development Co. Ltd Cellular blood markers for early diagnosis of als and for als progression

Also Published As

Publication number Publication date
JP6276252B2 (ja) 2018-02-07
WO2013144957A1 (en) 2013-10-03
US20150057176A1 (en) 2015-02-26
CA2907909A1 (en) 2013-10-03
CN104471394A (zh) 2015-03-25
JP2015511721A (ja) 2015-04-20
AU2013239070A1 (en) 2014-11-13
EP2831584A4 (en) 2015-10-07
CN104471394B (zh) 2017-04-05
EP2831584B1 (en) 2020-06-17
IL234779A (en) 2017-12-31
ES2819174T3 (es) 2021-04-15
EP2831584A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
KR20140145173A (ko) 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
Larbi et al. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease
Cui et al. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis
Chen et al. Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood
Martins et al. Disease-specific expression of the serotonin-receptor 5-HT2C in natural killer cells in Alzheimer's dementia
Atkinson et al. Biological aging of CNS-resident cells alters the clinical course and immunopathology of autoimmune demyelinating disease
US20150209404A1 (en) Cellular blood markers for early diagnosis of als and for als progression
WO2019112520A1 (en) Immune response profiling of tumor-derived exosomes for cancer diagnosis
Seksenyan et al. Thymic involution, a co‐morbidity factor in amyotrophic lateral sclerosis
Qi et al. Overexpression of programmed cell death-1 and human leucocyte antigen-DR on circulatory regulatory T cells in out-of-hospital cardiac arrest patients in the early period after return of spontaneous circulation
KR20220034769A (ko) 임상적으로 진단된 알츠하이머병 피험자의 혈액 샘플을 사용한 알츠하이머병 바이오마커
EP3128327B1 (en) Method for detecting smn protein expression
Frisullo et al. The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis
CN117460956A (zh) 外周血巨噬细胞在制备用于阿尔兹海默病诊断、预后及治疗的试剂和/或药物中的应用
Alsahebfosoul et al. Evaluation of soluble human leukocyte antigen-G (sHLA-G) isoforms and regulatory T cells in relapsing-remitting multiple sclerosis
KR102199141B1 (ko) 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
WO2025078628A1 (en) Prognosis method of multiple sclerosis
JP2025099732A (ja) 慢性移植片対宿主病の発症を予測するためのバイオマーカー、および判定方法
Diwan et al. Evaluation of serum beta-2 microglobulin as a diagnostic and prognostic marker in oral squamous cell carcinoma and leukoplakia
Na et al. The Influence of Gender on CD4+ Treg Cell Function in Acute Ischemic Stroke Prognosis Authors
Barupal Assessment of D-dimer levels in stroke patients
Vitiligo Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases
Rodríguez-Martín et al. Diagnosis of Diffuse Interstitial Lung Diseases: BAL Study-Its Utility for the Diagnosis
Younkin et al. Trisha M. Stan1, Philipp A. Jaeger1, Markus Britschgi1, Daniela Berdnik1, Ruo-Pan Huang2, Bradley F. Boeve3, Adam L. Boxer4, Nicole Finch5, Gabriela K. Fragiadakis6, Robert Bruggner6, Neill R. Graff-Radford5, Ruochun Huang4, Hudson Johns1, Anna Karydas4, David S. Knopman3, Michael Leipold6, 7, Holden Maecker6, 7, Zachary Miller4, Ronald C. Petersen5, Rosa Rademakers5, Chung-Huan Sun1, Steve
CN117230144A (zh) 抑郁症诊断、药物治疗效果预测的生物标志物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141024

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid